Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine.
Zhuo Z, Yu Y, Wang M, Li J, Zhang Z, Liu J, Wu X, Lu A, Zhang G, Zhang B. · 2017
Read Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine. by Zhuo Z, Yu Y, Wang M, Li J, Zhang Z, Liu J, Wu X, Lu A, Zhang G, Zhang B. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5666824.txt.
Introduction
Zhuo and co-authors present a review in the International Journal of Molecular Sciences. It covers SELEX technology and aptamer use in biomedicine. Aptamers are short DNA or RNA strands that bind targets tightly. SELEX selects them from huge random libraries over repeated rounds. More than 2,000 aptamers have been generated so far. Targets range from metal ions to whole cells.
Few aptamer products have reached clinical or industrial use. Only one aptamer drug has won approval to date. Selection stays slow, with low success rates. Performance inside the body also remains uncertain. The review weighs limits and recent advances in selection. It compares methods for measuring binding strength. Clinical progress and hurdles get full discussion.
Catalog record
| CREATOR | Zhuo Z, Yu Y, Wang M, Li J, Zhang Z, Liu J, Wu X, Lu A, Zhang G, Zhang B. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Recent Advances in SELEX Technology and Aptamer Applications in Biomedicine By Zhenjian Zhuo, Yuanyuan Yu, Maolin Wang, Jie Li, Zongkang Zhang, Jin Liu, Xiaohao Wu, Aiping Lu, Ge Zhang, Baoting Zhang Published in: International Journal of Molecular Sciences DOI: 10.3390/ijms18102142 ABSTRACT Abstract Aptamers are short DNA/RNA oligonucleotides capable of binding to target molecules with high affinity and specificity. The process of selecting an aptamer is called Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Thanks to the inherit merits, aptamers have been used in a wide range of applications, including disease diagnosis, targeted delivery agents and therapeutic uses. To date, great achievements regarding the selection, modifications and application of aptamers have been made. However, few aptamer-based products have already successfully entered into clinical and industrial use. Besides, it is still a challenge to obtain aptamers with high affinity in a more efficient way. Thus, it is important to comprehensively review the current shortage and achievement of aptamer-related technology. In this review, we first present the limitations and notable advances of aptamer selection. Then, we compare the different methods used in the kinetic characterization of aptamers. We also discuss the impetus and developments of the clinical application of aptamers. Keywords: aptamer, SELEX, selection, targeted drug delivery systems, therapy 1. INTRODUCTION Aptamers are a class of agents that act as affinity probes or molecular recognition elements for diagnostic or therapeutic purposes. They are synthetic single-stranded DNAs or RNAs, which bind to target molecules with high affinity in three-dimensional shapes. The term ‘aptamer’ was derived from the combination of the Latin word aptus (‘to fit’) and the Greek word meros (‘part’). The process of aptamers’ selection, termed Systematic Evolution of Ligands by Exponential Enrichment (SELEX), was first developed in 1990 by Tuerk and Gold [1] and Ellington and Szostak [2], separately. To date, thousands of aptamers targeting amino acids, proteins, small metal ion, organic molecules, bacteria, viruses, whole cells and animals have been generated [3]. These aptamers have been widely applied in analytical, bioanalytical, imaging, diagnostic and therapeutic fields. The following factors might contribute to the binding affinity between aptamers and their targets: hydrogen bonding, structure compatibility, stacking of aromatic rings, electrostatic and hydrophobic interactions and van der Waals forces [4]. Aptamers are highly comparable to antibodies, with the characteristics of binding to their targets with high affinity and specificity. Due to the advantages of the aptamers against antibodies listed in Table 1, aptamers have been increasing in popularity since their appearance. It is reported that more than 2000 aptamers have been generated during the past 30 years [5]. Despite great achievements, there still exists a larger lag in the successful clinical use of therapeutic aptamers than that of therapeutic antibodies. Only one aptamer, pegaptanib (Macugen; Pfizer/Eyetech), has been approved for clinical use [6]. Moreover, this Vascular Endothelial Growth Factor (VEGF)-targeted aptamer still fails to surpass anti-VEGF monoclonal antibodies such as ranibizumab (Lucentis; Genentech, San Francisco, CA, USA) and bevacizumab (Avastin; Genentech) in therapeutic effects [7]. Currently, two main barriers are attributed to the impediment of aptamer development and application. First, the SELEX process is still time consuming, and the successful rates are low. Second, most of the current aptamers are obtained in vitro, and whether they can function in vivo needs to be elucidated. [Table: Merits of nucleic acid aptamers over protein antibodies.] Herein, we first highlight the limitations and technological advances in the selection of aptamers. Then, the applications of aptamer for diagnosis in biomedicine are discussed. We also offer an overview of the clinical application of aptamers. We hope that this review will provide a better understanding for the development of aptamers. 2. LIMITATIONS AND ADVANCEMENTS IN APTAMER SELECTION In 1990, two laboratories independently developed SELEX. Since then, great modifications and improvements have been achieved. The conventional SELEX method mainly consists of the following three steps: selection, partitioning and amplification (Figure 1). Before the selection, a library of oligonucleotides is synthesized, which generally contains up to 1015 different unique sequences [1]. Each unique sequence contains random bases (20–50 nt) flanked by two conserved primer binding sites, which are used for PCR amplification by annealing primers. In the selection step, the library is incubated with target molecules for the indicated time. After incubation, the unbound sequences are separated from those that bound by different methods. The target-bound sequences are amplified by PCR (DNA SELEX) or reverse transcription PCR (RNA SELEX). The PCR products, being a new sub-pool, are utilized for the next round of selection. After several selection rounds, the enriched sequences are sequenced, and their binding abilities are further evaluated. Generally, it takes from weeks to months to obtain specific aptamer candidates, and the hit rates are low. Thus, the obtainment of high quality aptamers against relevant targets still remains a bottleneck. To shorten the selection time and enhance the hit rates, several modified SELEX methods have been set up. [Figure: Schematic illustration of the SELEX process for the DNA and RNA library.] 2.1. Negative SELEX Generally, the target molecules are attached to the immobilization matrix, which enables partition. During the selection period, some of the sequences might unwantedly bind to the immobilization matrix, causing false positive results. To eliminate such a possibility, Ellington and Szostak put forward a new method called negative SELEX in 1992 [8]. After three selection cycles, they incubated the library with purification support agarose as negative selection. The non-specific binding sequences were removed from each pool. The affinity of the resultant aptamers was about 10-times higher than that of aptamers obtained without negative selection. After that, most of the modified SELEX incorporated this process to eliminate nonspecific sequences generated by their binding to the immobilization matrix. 2.2. Counter SELEX Counter SELEX is similar to negative SELEX in procedure and purpose, except that counter SELEX uses similar target molecules as incubation subjects. The counter SELEX method was introduced by Jenison et al. in 1994 to enhance the specificity of aptamers [9]. Compared to traditional SELEX, counter SELEX adds an additional step using structurally-similar targets to incubate with aptamers to effectively discriminate non-specific oligonucleotides. This procedure has been dramatically applied to other modified SELEX methods to obtain more specific aptamers [10,11,12]. It is to be noted that the prominent difference between counter SELES and negative SELEX is their use of different incubation objects. 2.3. Capillary Electrophoresis SELEX In general, it takes about more than 15 rounds to obtain aptamers using the conventional SELEX method, which is labor intensive and time consuming. In 2004, a modified SELEX method called Capillary Electrophoresis SELEX (CE-SELEX) was developed [13,14]. CE-SELEX separates the target bounded sequences from unbound sequences by the difference in electrophoretic mobility, which is a highly efficient separation method. This method enables the selection of aptamer candidates with high affinity, while reducing the selection rounds to 1–4 from nearly 20 in conventional SELEX. Up to now, several aptamers have been successfully selected using CE-SELEX [15,16]. In order to further accelerate the selection procedure and to minimize the DNA amplification bias caused by the repetitive steps of PCR, modified selection methods have been developed. Another CE-based technology, which is called non-SELEX, selects an aptamer without amplification [17]. This technology utilizes Non-Equilibrium Capillary Electrophoresis of Equilibrium Mixtures (NECEEM), a highly efficient